Skip to main content
OpenTrials
Completed

NCT Number: NCT03470012

Adhesive Tape Trauma Evaluation of a New Gentle Tape in Healthy Infant Subjects

The objective of this study is to determine the relative gentleness of a new medical tape.

Completed

Looking for future studies?

Notify Me

Key information

Age range

6 month–4 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

cyberDERM, inc.

Broomall, Pennsylvania, 19008, United States

About this study

The objective of this study is to determine the relative gentleness of a new medical tape. A three-prong multidimensional evaluation consisting of expert grader, subject discomfort assessment, and laboratory assessments was used. One pre-study visit took place up to 7 days prior to the start of the study. The study was conducted over two days with one tape sample applied and removed. Assessments were taken on the final day. This was to mimic a normal tape application in health care practice.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Subjects will be infants or children of either gender who meet the following criteria:

  • Who are healthy and who have intact skin at the test site with a baseline score of 0 for erythema
  • Who are between the ages of 6 months - 4 years of age (48 months)
  • Who have a Fitzpatrick Skin Type of I, II or III
  • Whose parent or legal representative agrees to not use any products (i.e. topical medications, creams, powders or ointments) on the test sites for 24 hours prior to the study start date
  • Whose parent or legal representative agrees to sponge bathe their child during the study but agrees to not bathe their child 1 hour before each visit.
  • Whose parent or legal representative agrees to not soak the tape during a sponge bath. If the site gets wet, parent or legal representative agrees to pat their child's back dry (no rubbing).
  • Whose parent or legal representative is willing to sign the Informed Consent Form (with photo release) and HIPAA Authorization.

Exclusion criteria

  • Who are known to be developmentally delayed
  • Who have any known allergy or sensitivity to tapes
  • Who have sunburn, skin infection or scars, moles, or other blemishes on the back that would obscure grading of the test site
  • Who have had any exposure to other topical medications, creams, powders, or ointments on the test sites 24 hours prior to the start of the study
  • Who have had a strep infection within the 2 weeks prior to the start of the study
  • Who have a history of uncontrolled diabetes, psoriasis, any active dermatitis, or recent history of dermatitis or skin reactions
  • Has participated in any study in the last 2 weeks, or are currently participating in another study, or are scheduled to participate in another study during this study period.
  • Has any other skin disorders that, in the opinion of the investigator, will interfere with the study results or will increase undue risk for the child.

Treatment and study plan

Multi-Purpose Gentle Tape

Device

The Multi-Purpose Gentle Tape is a general purpose medical adhesive tape for medical applications used primarily to secure dressings, lightweight tubing, and devices to skin.

Primary outcomes

  1. The Face, Legs, Activity, Cry, Consolability (FLACC) Score.

    Time frame: 24 Hours after initial tape application and after tape removal. Change in FLACC score between the time of tape removal and baseline.

    The Face, Legs, Activity, Cry, Consolability (FLACC) scale is a measurement used to assess pain for children Participants between the ages of 2 months and 7 years or individuals that are unable to communicate their pain. The scale is scored in a range of 0-10 with 0 representing no pain. Lower values represent lessening pain on the scale. At the 24 hour visit , a baseline FLACC score was recorded with the tape still in place. The tape was then removed and a FLACC score was recorded after removal. The reported value is the difference between FLACC after removal and FLACC at baseline.

Sponsors and collaborators

Lead sponsor

Solventum US LLC

Industry

Collaborators

  • 3M

Registry information

Important dates

Study start
2018
Primary completion
2018
Study completion
2018
First posted
Mar 19, 2018
Registry last updated
Oct 2, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.